Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

BA-BE Studies: SOP for Use of LC-MS/MS in BA/BE Studies – V 2.0

Posted on By

BA-BE Studies: SOP for Use of LC-MS/MS in BA/BE Studies – V 2.0

Standard Operating Procedure for Use of LC-MS/MS in Bioavailability and Bioequivalence Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/160/2025
Supersedes SOP/BA-BE/160/2022
Page No. Page 1 of 12
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define the standard procedure for using Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) for the quantification of drug compounds and metabolites in biological matrices during BA/BE studies.

2. Scope

This SOP is applicable to all bioanalytical scientists, analysts, and instrument operators involved in LC-MS/MS-based analysis of plasma and biological samples for pharmacokinetic evaluations in BA/BE studies.

3. Responsibilities

  • Analyst: Operates the LC-MS/MS as per validated method, performs basic maintenance, and documents data.
  • QA Personnel: Reviews data acquisition and chromatographic quality; investigates any deviations.
  • Lab Manager: Ensures system readiness, calibration, and compliance with regulatory guidelines.

4. Accountability

The Head of Bioanalytical Laboratory is accountable for ensuring proper use, qualification, and maintenance of LC-MS/MS instrumentation in compliance with ICH, FDA, EMA, and GLP requirements.

See also  BA-BE Studies: SOP for Handling Expired Reference Products - V 2.0

5. Procedure

5.1 Pre-Operational Checks

  1. Ensure the LC-MS/MS system is calibrated and previously qualified (IQ/OQ/PQ completed).
  2. Check autosampler tray cleanliness, solvent levels, and waste container status.
  3. Review environmental conditions (temperature/humidity within acceptable range).

5.2 Mobile Phase and Column Preparation

  1. Prepare mobile phases as per validated method (e.g., water + 0.1% formic acid and acetonitrile).
  2. Degas mobile phases using ultrasonic bath or inline degasser.
  3. Install validated LC column and equilibrate for at least 30 minutes at specified flow rate.

5.3 Tuning and Calibration of MS

  1. Perform system tuning using the specified tuning solution (e.g., polytyrosine or PPG).
  2. Adjust source parameters (e.g., curtain gas, collision energy) for optimized ion transmission.
  3. Document instrument tuning in Annexure-1: Tuning Log.

5.4 Sample Injection and Sequence Setup

  1. Create an injection sequence that includes:
    • Blank samples
    • Calibration standards (low to high)
    • Quality control (QC) samples
    • Study samples
    • Reinjected QC and blanks for carryover
  2. Input batch details and file names in the data acquisition software.
  3. Run the sequence ensuring the MS/MS transitions are correctly monitored (MRM mode).
See also  BA-BE Studies: SOP for Label Generation and Sample Barcode Management - V 2.0

5.5 Data Acquisition

  1. Monitor signal intensity, retention time, and baseline noise throughout the run.
  2. Ensure injection reproducibility and peak integrity for QC samples.
  3. Any instrument interruption must be documented in the Instrument Interruption Log (Annexure-2).

5.6 System Suitability and Acceptance Criteria

  1. Verify that retention time, signal-to-noise ratio, and peak area of calibrators fall within acceptance criteria.
  2. Evaluate carryover by injecting blanks post high-concentration standards.
  3. Reject runs with failed calibration curve or QC deviation > ±15% (±20% at LLOQ).

5.7 Post-Run Activities

  1. Rinse LC lines with mobile phase and then water to prevent salt or buffer deposits.
  2. Shutdown system if not in use: stop flow, vent MS source, turn off ion source gases.
  3. Save raw data, transfer to secured server, and archive sequence files.

5.8 Troubleshooting

  1. Common issues:
    • No signal – Check spray voltage, capillary clog, or sample prep error
    • Drift in retention time – Verify pump pressure and mobile phase integrity
    • High background – Clean ion source or replace cone/skimmer

5.9 Documentation and Review

  1. Maintain batch run details in Annexure-3: LC-MS/MS Run Summary Sheet.
  2. Review integration and audit trail per GxP requirements.

6. Abbreviations

  • BA/BE: Bioavailability/Bioequivalence
  • LC-MS/MS: Liquid Chromatography – Tandem Mass Spectrometry
  • IQ/OQ/PQ: Installation/Operational/Performance Qualification
  • MRM: Multiple Reaction Monitoring
  • QC: Quality Control
See also  BA-BE Studies: SOP for Protein Precipitation Method in Plasma - V 2.0

7. Documents

  1. Tuning Log – Annexure-1
  2. Instrument Interruption Log – Annexure-2
  3. LC-MS/MS Run Summary Sheet – Annexure-3

8. References

  • ICH M10: Bioanalytical Method Validation
  • FDA/EMA LC-MS/MS Regulatory Guidelines
  • Instrument Vendor Manuals (e.g., Sciex, Agilent, Waters)

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Tuning Log

Date Instrument ID Tuning Solution Operator Comments
17/04/2025 LCMS-01 PPG Rajesh Kumar Successful

Annexure-2: Instrument Interruption Log

Date Batch ID Nature of Issue Corrective Action Reviewer
17/04/2025 BE-101 No spray Cleaned source Sunita Reddy

Annexure-3: LC-MS/MS Run Summary Sheet

Run Date Batch No. Analyst No. of Samples Deviation
17/04/2025 BE-101 Vinay Pawar 48 No

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial release New SOP QA Head
17/04/2025 2.0 Integrated MRM settings and run summary tracking GxP Audit Feedback QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Biosimilars: SOP for pCO₂ and pO₂ Monitoring in Bioreactor Operations – V 2.0
Next Post: API Manufacturing: SOP for Operation of FTIR Spectrometer – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version